These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. [Treatment of immune deficient neuropathies with intravenous polyvalent immunoglobulins. An open study of 16 cases]. Hoang-Xuan K; Léger JM; Ben Younes-Chennoufi A; Saidi H; Bouche P; Baumann N; Brunet P Rev Neurol (Paris); 1993; 149(6-7):385-92. PubMed ID: 8303157 [TBL] [Abstract][Full Text] [Related]
27. Use of intravenous immunoglobulin G (IVIG). Looney RJ; Huggins J Best Pract Res Clin Haematol; 2006; 19(1):3-25. PubMed ID: 16377538 [TBL] [Abstract][Full Text] [Related]
28. Safety considerations in IGIV utilization. Siegel J Int Immunopharmacol; 2006 Apr; 6(4):523-7. PubMed ID: 16504914 [TBL] [Abstract][Full Text] [Related]
29. The new generation of liquid intravenous immunoglobulin formulations in patient care: a comparison of intravenous immunoglobulins. Stein MR Postgrad Med; 2010 Sep; 122(5):176-84. PubMed ID: 20861601 [TBL] [Abstract][Full Text] [Related]
35. Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial. Roifman CM; Schroeder H; Berger M; Sorensen R; Ballow M; Buckley RH; Gewurz A; Korenblat P; Sussman G; Lemm G Int Immunopharmacol; 2003 Sep; 3(9):1325-33. PubMed ID: 12890430 [TBL] [Abstract][Full Text] [Related]